Biogen (BIIB) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $3.8 billion.
- Biogen's Cash & Current Investments rose 6066.11% to $3.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.8 billion, marking a year-over-year increase of 6066.11%. This contributed to the annual value of $3.8 billion for FY2025, which is 6066.11% up from last year.
- Latest data reveals that Biogen reported Cash & Current Investments of $3.8 billion as of Q4 2025, which was up 6066.11% from $4.0 billion recorded in Q3 2025.
- In the past 5 years, Biogen's Cash & Current Investments registered a high of $6.1 billion during Q2 2023, and its lowest value of $1.0 billion during Q4 2023.
- Moreover, its 5-year median value for Cash & Current Investments was $3.0 billion (2021), whereas its average is $3.3 billion.
- Its Cash & Current Investments has fluctuated over the past 5 years, first tumbled by 7868.8% in 2024, then skyrocketed by 14183.73% in 2025.
- Biogen's Cash & Current Investments (Quarter) stood at $3.8 billion in 2021, then increased by 28.67% to $4.9 billion in 2022, then crashed by 78.54% to $1.0 billion in 2023, then surged by 126.21% to $2.4 billion in 2024, then skyrocketed by 60.66% to $3.8 billion in 2025.
- Its Cash & Current Investments was $3.8 billion in Q4 2025, compared to $4.0 billion in Q3 2025 and $2.8 billion in Q2 2025.